The global extracorporeal membrane oxygenation (ECMO) machine market size was estimated to be USD 311.9 million in 2023 and is expected to reach at USD 594.6 million by 2033 with a CAGR of 6.04% during the forecast period 2024-2034. Increasing prevalence of cardiopulmonary disease, respiratory failure, & chronic obstructive pulmonary disease (COPD), growing adoption of extracorporeal membrane oxygenation machine (ECMO), rising technological advancement, surge in number of hospitals offering ECMO services, increasing number of awareness programs regarding ECMO procedures, growing geriatric population, surge in launch of advanced products, and rising approvals of technologically advanced systems by U.S. Food and Drug Administration (FDA) are the key factors propelling the market growth.
Rising approvals of technologically advanced systems by U.S. Food and Drug Administration (FDA) is predicted to boost the market growth during the forecast period. The growing utilization of extracorporeal membrane oxygenation machines (ECMO) has driven advancements in technology within these systems, leading to enhanced patient results. For instance, in May 2023, Medtronic has achieved FDA approval for its Micra AV2 and VR2 advanced leadless, miniature pacing systems. These pacemakers hold the distinction of being the world's tiniest, and they provide longer battery life and more user-friendly programming than their predecessors. The extraordinary algorithms in the Micra AV2 also automatically control AV synchronization and balance the upper and lower chambers of the heart.
By component, oxygenators was the highest revenue-grossing segment in the global extracorporeal membrane oxygenation (ECMO) machine market in 2023 owing to rising prevalence of various coronary heart diseases & strokes due to changing lifestyles, growing demand for coronary artery bypass procedures, increasing introduction of technologically advanced systems. For instance, in July 2022, Inspira Technologies OXY B.H.N. Ltd has unveiled the Liby System, an advanced life support system designed for the treatment of individuals facing life-threatening heart and lung failure. Additionally, pumps is predicted to grow at fastest CAGR during the forecast period owing to the increasing usage of pumps in ECMO procedures, availability of various types of pumps including impeller, roller, & centrifugal, and surge in launch of advanced products.
By modality, veno-arterial was the highest revenue-grossing segment in the global extracorporeal membrane oxygenation (ECMO) machine market in 2023 owing to the beneficial applications offered by this device type, growing prevalence of cardiac disorder, rising favourable reimbursement policies, increasing usage in treating patients with cardiac arrest, and surge in regulatory approvals. For instance, in March 2023, Getinge has obtained premarket approval from the FDA in the United States for its covered stent system known as iCast. This system is designed for addressing iliac arterial occlusive disease in patients. The iCast covered stent system, which is marketed as Advanta V12 covered stent outside the US, has been in use for two decades and holds the distinction of being the most extensively evaluated balloon-expandable polytetrafluoroethylene (ePTFE)-covered stent worldwide. Additionally, veno-venous is predicted to grow at fastest CAGR during the forecast period owing to the increasing incidence of chronic obstruction pulmonary disease and surge in number of lung transplant procedures.
By patient type, adult was the highest revenue-grossing segment in the global extracorporeal membrane oxygenation (ECMO) machine market in 2023 owing to surge in number of lung transplant procedures in adult population, growing prevalence of cardiac & respiratory diseases in adults, rising adoption of sedentary lifestyle, and increasing focus on development of advanced products by market players. Additionally, pediatric is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of cardiac illness & pneumonia among children, growing number of children with various pulmonary heart diseases, and rising launch of advanced systems by market players. For instance, in October 2022, Eurosets has introduced Colibrì to the market, a lightweight life-saving system designed to temporarily take over cardiac and pulmonary functions in adult, neonatal, and pediatric patients. This system proves particularly valuable in critical rescue scenarios and is accompanied by a specialized backpack featuring a centrally balanced hook, facilitating its transportation via air vehicles like drones or helicopters.
By application, respiratory was the highest revenue-grossing segment in the global extracorporeal membrane oxygenation (ECMO) machine market in 2023 owing to rising prevalence of respiratory disorder, increasing awareness of ECMO procedures, growing launch of advanced devices, and surge in regulatory approvals. Additionally, cardiac is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of cardiac surgery, increasing awareness regarding ECMO machines in cardiac surgery, and surge in strategic initiatives such as partnership & collaboration within market players. For instance, in January 2023, Getinge has established a strategic collaboration with kinderherzen, a Swedish nonprofit organization, with the aim of assisting children dealing with congenital heart defects. Getinge has supplied a variety of medical technology products to aid kinderherzen in their efforts to create a mobile unit for cardiac surgery. This initiative is intended to offer treatment to children afflicted by congenital heart defects.
By end-user, hospitals was the highest revenue-grossing segment in the global extracorporeal membrane oxygenation (ECMO) machine market in 2023 owing to the rising number of hospitals offering ECMO services and surge approvals of advanced systems by regulatory bodies. For instance, in November 2022, LivaNova PLC has disclosed the acquisition of a 510(k) clearance from the FDA for its LifeSPARC ECMO system. LifeSPARC is an innovative Advanced Circulatory Support (ACS) pump and controller system developed by the company. This system streamlines ECMO procedures, ensuring that medical facilities of diverse scales and types can avail themselves of advanced life support capabilities. Additionally, Specialty clinics is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of respiratory disorders and growing adoption of advanced technologies by clinics.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in government support for quality healthcare, presence of leading market players, growing prevalence of chronic obstructive pulmonary disease, rising favorable reimbursement policies, increasing product launches, and surge in regulatory approvals. For instance, in January 2023, CytoSorbents Corporation has revealed that Health Canada has granted approval to involve Canadian sites in the randomized controlled trial known as STAR-T, which is a pivotal study focusing on the Safe and Timely Antithrombotic Removal of Ticagrelor. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing healthcare expenditure by the government & private organizations, increasing prevalence of respiratory disorders, surge in number of lung transplant procedures, rising regulatory approvals, and growing collaborations within market players for the development of novel systems. For instance, in February 2023, The China Aerospace Science and Technology Corporation (CASC), a state-owned aerospace company, and Peking Union Medical College Hospital (PUMCH) have collaboratively unveiled a domestically produced extracorporeal membrane oxygenation (ECMO) system, often referred to as the artificial lung/heart system. This system features core components that are entirely developed within the country and boasts world-class performance. It is anticipated that this innovation will significantly lower patients' healthcare costs, as its overall performance and metrics are on par with or even surpass the global standards for similar products.
Rising approvals of technologically advanced systems by U.S. Food and Drug Administration (FDA) is predicted to boost the market growth during the forecast period. The growing utilization of extracorporeal membrane oxygenation machines (ECMO) has driven advancements in technology within these systems, leading to enhanced patient results. For instance, in May 2023, Medtronic has achieved FDA approval for its Micra AV2 and VR2 advanced leadless, miniature pacing systems. These pacemakers hold the distinction of being the world's tiniest, and they provide longer battery life and more user-friendly programming than their predecessors. The extraordinary algorithms in the Micra AV2 also automatically control AV synchronization and balance the upper and lower chambers of the heart.
By component, oxygenators was the highest revenue-grossing segment in the global extracorporeal membrane oxygenation (ECMO) machine market in 2023 owing to rising prevalence of various coronary heart diseases & strokes due to changing lifestyles, growing demand for coronary artery bypass procedures, increasing introduction of technologically advanced systems. For instance, in July 2022, Inspira Technologies OXY B.H.N. Ltd has unveiled the Liby System, an advanced life support system designed for the treatment of individuals facing life-threatening heart and lung failure. Additionally, pumps is predicted to grow at fastest CAGR during the forecast period owing to the increasing usage of pumps in ECMO procedures, availability of various types of pumps including impeller, roller, & centrifugal, and surge in launch of advanced products.
By modality, veno-arterial was the highest revenue-grossing segment in the global extracorporeal membrane oxygenation (ECMO) machine market in 2023 owing to the beneficial applications offered by this device type, growing prevalence of cardiac disorder, rising favourable reimbursement policies, increasing usage in treating patients with cardiac arrest, and surge in regulatory approvals. For instance, in March 2023, Getinge has obtained premarket approval from the FDA in the United States for its covered stent system known as iCast. This system is designed for addressing iliac arterial occlusive disease in patients. The iCast covered stent system, which is marketed as Advanta V12 covered stent outside the US, has been in use for two decades and holds the distinction of being the most extensively evaluated balloon-expandable polytetrafluoroethylene (ePTFE)-covered stent worldwide. Additionally, veno-venous is predicted to grow at fastest CAGR during the forecast period owing to the increasing incidence of chronic obstruction pulmonary disease and surge in number of lung transplant procedures.
By patient type, adult was the highest revenue-grossing segment in the global extracorporeal membrane oxygenation (ECMO) machine market in 2023 owing to surge in number of lung transplant procedures in adult population, growing prevalence of cardiac & respiratory diseases in adults, rising adoption of sedentary lifestyle, and increasing focus on development of advanced products by market players. Additionally, pediatric is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of cardiac illness & pneumonia among children, growing number of children with various pulmonary heart diseases, and rising launch of advanced systems by market players. For instance, in October 2022, Eurosets has introduced Colibrì to the market, a lightweight life-saving system designed to temporarily take over cardiac and pulmonary functions in adult, neonatal, and pediatric patients. This system proves particularly valuable in critical rescue scenarios and is accompanied by a specialized backpack featuring a centrally balanced hook, facilitating its transportation via air vehicles like drones or helicopters.
By application, respiratory was the highest revenue-grossing segment in the global extracorporeal membrane oxygenation (ECMO) machine market in 2023 owing to rising prevalence of respiratory disorder, increasing awareness of ECMO procedures, growing launch of advanced devices, and surge in regulatory approvals. Additionally, cardiac is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of cardiac surgery, increasing awareness regarding ECMO machines in cardiac surgery, and surge in strategic initiatives such as partnership & collaboration within market players. For instance, in January 2023, Getinge has established a strategic collaboration with kinderherzen, a Swedish nonprofit organization, with the aim of assisting children dealing with congenital heart defects. Getinge has supplied a variety of medical technology products to aid kinderherzen in their efforts to create a mobile unit for cardiac surgery. This initiative is intended to offer treatment to children afflicted by congenital heart defects.
By end-user, hospitals was the highest revenue-grossing segment in the global extracorporeal membrane oxygenation (ECMO) machine market in 2023 owing to the rising number of hospitals offering ECMO services and surge approvals of advanced systems by regulatory bodies. For instance, in November 2022, LivaNova PLC has disclosed the acquisition of a 510(k) clearance from the FDA for its LifeSPARC ECMO system. LifeSPARC is an innovative Advanced Circulatory Support (ACS) pump and controller system developed by the company. This system streamlines ECMO procedures, ensuring that medical facilities of diverse scales and types can avail themselves of advanced life support capabilities. Additionally, Specialty clinics is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of respiratory disorders and growing adoption of advanced technologies by clinics.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in government support for quality healthcare, presence of leading market players, growing prevalence of chronic obstructive pulmonary disease, rising favorable reimbursement policies, increasing product launches, and surge in regulatory approvals. For instance, in January 2023, CytoSorbents Corporation has revealed that Health Canada has granted approval to involve Canadian sites in the randomized controlled trial known as STAR-T, which is a pivotal study focusing on the Safe and Timely Antithrombotic Removal of Ticagrelor. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the growing healthcare expenditure by the government & private organizations, increasing prevalence of respiratory disorders, surge in number of lung transplant procedures, rising regulatory approvals, and growing collaborations within market players for the development of novel systems. For instance, in February 2023, The China Aerospace Science and Technology Corporation (CASC), a state-owned aerospace company, and Peking Union Medical College Hospital (PUMCH) have collaboratively unveiled a domestically produced extracorporeal membrane oxygenation (ECMO) system, often referred to as the artificial lung/heart system. This system features core components that are entirely developed within the country and boasts world-class performance. It is anticipated that this innovation will significantly lower patients' healthcare costs, as its overall performance and metrics are on par with or even surpass the global standards for similar products.
Segmentation: Extracorporeal Membrane Oxygenation (ECMO) Machine Market Report 2022 - 2033
Extracorporeal Membrane Oxygenation (ECMO) Machine Market Analysis & Forecast by Component 2022 - 2033 (Revenue USD Mn)
- Oxygenator
- Pumps
- Cannula
- Controllers
- Accessories
Extracorporeal Membrane Oxygenation (ECMO) Machine Market Analysis & Forecast by Modality 2022 - 2033 (Revenue USD Mn)
- Veno-Venous
- Arterio-Venous
- Veno-Arterial
Extracorporeal Membrane Oxygenation (ECMO) Machine Market Analysis & Forecast by Patient Type 2022 - 2033 (Revenue USD Mn)
- Neonates
- Pediatric
- Adult
Extracorporeal Membrane Oxygenation (ECMO) Machine Market Analysis & Forecast by Application 2022 - 2033 (Revenue USD Mn)
- ECPR
- Cardiac
- Respiratory
Extracorporeal Membrane Oxygenation (ECMO) Machine Market Analysis & Forecast by End-user 2022 - 2033 (Revenue USD Mn)
- Specialty Clinics
- Hospitals
Extracorporeal Membrane Oxygenation (ECMO) Machine Market Analysis & Forecast by Region 2022 - 2033 (Revenue USD Mn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Extracorporeal Membrane Oxygenation (ECMO) Machine Market: Component Estimates & Trend Analysis
8. Extracorporeal Membrane Oxygenation (ECMO) Machine Market: Modality Estimates & Trend Analysis
9. Extracorporeal Membrane Oxygenation (ECMO) Machine Market: Patient Type Estimates & Trend Analysis
10. Extracorporeal Membrane Oxygenation (ECMO) Machine Market: Application Estimates & Trend Analysis
11. Extracorporeal Membrane Oxygenation (ECMO) Machine Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Extracorporeal Membrane Oxygenation (ECMO) Machine Market
14. Europe Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market
15. Asia Pacific Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market
16. Latin America Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market
17. MEA Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Getinge
- Medtronic plc
- CytoSorbents Corporation
- Sorin Group
- LivaNova PLC
- Terumo Cardiovascular Systems Corporation
- Eurosets
- MAQUET Holding B.V. & Co. KG
- ABIOMED
- Medos Medizintechnik AG
- Microport Scientific Corporation
- Nipro Medical Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 311.97 Million |
| Forecasted Market Value ( USD | $ 594.67 Million |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
